AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based biopharmaceutical leader, has announced a plan to invest $135 million in its biopharmaceutical manufacturing facility in Södertälje, Sweden. This marks the first significant investment in the Sweden Biomanufacturing Center since its inauguration in 2021.
The funding will facilitate a 2,700 square meter expansion of the existing infrastructure, increasing floor space by 50% and enabling the filling of biologic drugs in pre-filled syringes. Production in the new extension is set to commence in the fourth quarter of 2027.- Flcube.com
